QMS Medical Allied Services Ltd
Incorporated in 2017, QMS Medical Allied Services Ltd is a manufacturer and distributor of medical devices[1]
- Market Cap ₹ 151 Cr.
- Current Price ₹ 78.0
- High / Low ₹ 113 / 69.0
- Stock P/E 16.8
- Book Value ₹ 53.2
- Dividend Yield 0.64 %
- ROCE 20.7 %
- ROE 12.5 %
- Face Value ₹ 10.0
Pros
Cons
- Promoter holding has decreased over last quarter: -5.56%
- Company has a low return on equity of 12.4% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 52 | 73 | 122 | 146 | 104 | 122 | 145 | 155 | |
| 0 | 47 | 63 | 105 | 130 | 93 | 104 | 121 | 132 | |
| Operating Profit | 0 | 5 | 10 | 17 | 17 | 11 | 18 | 23 | 24 |
| OPM % | 12% | 9% | 13% | 14% | 11% | 11% | 15% | 16% | 15% |
| 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | |
| Interest | 0 | 0 | 1 | 1 | 2 | 2 | 3 | 6 | 8 |
| Depreciation | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 3 | 3 |
| Profit before tax | 0 | 4 | 9 | 15 | 14 | 9 | 12 | 14 | 13 |
| Tax % | 0% | 30% | 28% | 27% | 26% | 27% | 26% | 28% | |
| 0 | 3 | 6 | 11 | 11 | 6 | 9 | 10 | 9 | |
| EPS in Rs | 19.15 | 26.63 | 26.07 | 3.31 | 4.66 | 5.40 | 4.65 | ||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 10% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 15% |
| 3 Years: | 0% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 11% |
| 3 Years: | 2% |
| TTM: | 1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -17% |
| 1 Year: | -11% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 12% |
| Last Year: | 13% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 3 | 4 | 4 | 18 | 18 | 18 | 19 |
| Reserves | 0 | 3 | 6 | 17 | 27 | 53 | 61 | 70 | 84 |
| 0 | 5 | 12 | 20 | 32 | 26 | 2 | 28 | 83 | |
| 5 | 10 | 12 | 20 | 19 | 22 | 54 | 73 | 23 | |
| Total Liabilities | 5 | 18 | 33 | 60 | 82 | 118 | 135 | 189 | 208 |
| 0 | 0 | 3 | 10 | 8 | 25 | 24 | 22 | 25 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 48 | 46 |
| 5 | 18 | 30 | 50 | 75 | 91 | 108 | 115 | 138 | |
| Total Assets | 5 | 18 | 33 | 60 | 82 | 118 | 135 | 189 | 208 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 4 | 2 | -2 | -8 | 1 | 18 | |
| 0 | -0 | -4 | -8 | 2 | -25 | -2 | -48 | |
| 0 | 0 | 0 | 7 | 0 | 32 | -1 | -2 | |
| Net Cash Flow | 0 | 0 | 1 | 1 | 1 | -1 | -1 | -32 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 411 | 56 | 56 | 69 | 105 | 137 | 124 | 104 |
| Inventory Days | 22,891 | 76 | 108 | 82 | 80 | 140 | 172 | 176 |
| Days Payable | 26,124 | 75 | 78 | 73 | 56 | 91 | 90 | 74 |
| Cash Conversion Cycle | -2,822 | 58 | 86 | 77 | 129 | 187 | 205 | 206 |
| Working Capital Days | -91 | 20 | 27 | 28 | 57 | 138 | 244 | 224 |
| ROCE % | 121% | 65% | 54% | 30% | 14% | 17% | 21% |
Insights
In beta| Mar 2024 | Mar 2025 | |
|---|---|---|
| Number of B2B Health Camps Number |
|
|
| Number of Cities Presence Number |
||
| Number of Employees (Total Workforce) Number |
||
| Number of Healthcare Professionals (HCPs) Engagement Lakhs |
||
| Number of Institutional Clients Number |
||
| Number of Patient Service Programs (PSPs) Number |
||
| Number of Patients Tracked in Digital Ecosystem Lakhs |
||
| Number of SKUs Number |
||
| Serviceable Pin Codes Number |
||
Documents
Announcements
-
Press Release
16 March 2026 - QMS appoints Himani Pruthi as Strategy & Marketing Business Unit Head, effective March 16, 2026.
-
Analysts/Institutional Investor Meet/Con. Call Updates
2 March 2026 - QMS Medical to attend Arihant Bharat Connect virtual investor meeting on March 6, 2026 at 11:00 AM IST.
-
Investor Presentation
20 February 2026 - Q3 revenue ₹37.3cr, Q3 PAT ₹3.2cr; 9MFY26 revenue ₹128.5cr, 9MFY26 PAT ₹9.9cr.
-
Acquisition
19 February 2026 - Amendment: acquisition of Prometheus for Rs.78,00,000; completion by 30 Sept 2026 in tranches.
-
Monitoring Agency Report
14 February 2026 - CARE report on Rs.12.05 crore rights issue utilization for quarter ended Dec 31, 2025; Rs.0.01cr unutilized.
Annual reports
Concalls
-
Feb 2026TranscriptAI SummaryPPT
-
Nov 2025Transcript PPT
-
Aug 2025TranscriptPPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Sep 2023Transcript PPT
Business Overview:[1]
QMASL does marketing and distribution of medical products and medical education services to clinics, pharma, medical companies and also to individual users. These devices are sold directly in the brand of the manufacturer and are sold under the brand name Q Devices. Company manages the distribution for other brands viz. 3M, Heine, Rossmax, etc.